Candel Therapeutics, Inc.
No SEC Form 4 filings for $CADL in the last 30 days.
See all $CADL insider activity →Candel Therapeutics (CADL) has appointed Maria Ostrovsky as General Counsel, effective Nov. 3, 2026. The company plans to submit a BLA for aglatimagene in Q4 2026, according to the announcement.
Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.
H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CADL (Candel Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent CADL coverage spans financial news, corporate actions and technology.
Executive hire with limited immediate market impact.
Analyst upgrades and strong trial results could lift the stock.
Positive trial data supports higher valuation.
The option grant is a routine corporate action with limited immediate market impact.
Positive Phase 2a data could lift CADL as investors anticipate a pivotal Phase 3 readout and potential regulatory milestones.
AlphAI scores every news story that mentions CADL with an AI model for sentiment and relevance, and aggregates insider trades from Candel Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Candel Therapeutics (CADL) has appointed Maria Ostrovsky as General Counsel, effective Nov. 3, 2026. The company plans to submit a BLA for aglatimagene in Q4 2026, according to the announcement.
1 min readJefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.
2 min readH.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.
2 min readCandel Therapeutics (CADL) granted stock options to 4 new employees, totaling 85,900 shares at $10.44 per share. The options vest over 4 years, subject to continued service. The grants were made under Nasdaq Rule 5635(c)(4) and the Company's 2025 Inducement Plan. Candel is a clinical-stage biopharmaceutical company focused on cancer immunotherapies.
1 min readCandel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.
3 min readCandel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.
2 min readCandel Therapeutics (CADL) shares rose 9.3% premarket after BofA Securities upgraded the stock to Buy and raised the price target to $18.00 from $12.00, citing positive outlook for the biotech sector and key catalysts.
2 min readU.S. stock futures rose overnight after the Federal Reserve's 25 basis point rate hike, with Dow, S&P 500, and Nasdaq futures up 0.62%, 0.56%, and 0.57% respectively. The Fed's target rate now ranges from 3.75% to 4.00%. SpaceX (SPCX) shares climbed over 5% on Morgan Stanley's positive rating, while Fluence Energy (FLNC) dropped 15% after cutting fiscal 2026 guidance. Snap (SNAP) gained 2% after unveiling new AI products.
2 min readTak Paul Peter (Chief Executive Officer) sold 280,245 shares of Candel Therapeutics, Inc. (CADL) at an average of $11.28 ($10.46–$11.50, $3.16M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.
1 min readCandel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors • Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass.,
1 min read
